Pulmonary and neurobehavioral efficacies of AVR-48, a TLR4 modulator, in a preterm lamb model of bronchopulmonary dysplasia
AVR-48 is a promising novel candidate drug for further development in preventing BPD and has the potential to reduce the associated adverse neurodevelopmental sequelae in preterm neonates.
Authors
- Andrew Rebentisch (ORCID: https://orcid.org/0009-0008-4693-5182)
- Joanna Beachy (ORCID: https://orcid.org/0000-0001-5259-8786)
- Suchismita Acharya
- Adam S. Dayoub
- Kurt H. Albertine (ORCID: https://orcid.org/0000-0001-8497-0861)
- Vineet Bhandari (ORCID: https://orcid.org/0000-0002-4900-6636)
- Elaine Dawson
- Michael A. Simmons (ORCID: https://orcid.org/0000-0001-7808-2796)
- Eesha Acharya
- David M. Riley (ORCID: https://orcid.org/0000-0003-1072-6027)
- Emily Major
- Suhas G. Kallapur (ORCID: https://orcid.org/0000-0003-3160-8126)
- Mar Janna Dahl (ORCID: https://orcid.org/0000-0002-3808-7995)
- Sydney Bowen
- Jakob Van Boerum
- M. Borton
- Dale J. Christensen
Institutions
- University of North Texas (US)
- Texas Christian University (US)
- University of California, Los Angeles (US)
- University of North Texas Health Science Center (US)
- Duke University (US)
- University of Utah (US)
- Cooper University Hospital (US)
- Cooper Medical School of Rowan University (US)
- Ministry of AYUSH (IN)
- Duke Medical Center (US)
Publication Details
- Journal
- Respiratory Research
- Published
- 2025-08-25
- DOI
- https://doi.org/10.1186/s12931-025-03337-z
- Citations
- 1
- Primary Topic
- Neonatal Respiratory Health Research
- Type
- article
- Field-Weighted Citation Impact
- 1.52
Funders
- University of Utah
- National Institutes of Health